Toborzás még nem indult2. fázis
Randomised, Double-Blind, Crossover Study with Inhaled LABA, LAMA, and their Combination AERO-007
A legfontosabb adatok
- Ki végzi
- Aerorx Therapeutics Inc.
- Hol
- Németország3 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 2. fázis
- Résztvevők
- 40 fő, tervezett
- Kezdés
- 2026. dec. 1.
- Várható befejezés
- 2027. jún. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter összes feltétele (29)A regiszter feltételeinek elrejtése
Ki vehet részt
- Male or female aged 40 to 75 years, inclusive, at the time of informed consent
- Participants must agree not to donate semen or ova/oocytes from the time of informed consent and for 30 days following the last administered dose
- Willing and able to provide written informed consent
- Clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2026 for at least 12 months prior to Screening Visit 1
- Post-bronchodilator spirometry (after 10 to 30 minutes following 4 puffs of salbutamol/albuterol via metered dose inhaler [MDI] with a spacer) at Screening Visit 2 demonstrating the following: • FEV1 ≥40 and ≤ 80% of predicted normal (using the Global Lung Function Initiative [GLI] 2012 reference values) • FEV1/forced vital capacity (FVC) ratio < 0.70 • ≥ 150 mL increase from pre-bronchodilator FEV1 following 4 puffs of salbutamol/albuterol
- Ability to change current COPD therapy and discontinue long-acting bronchodilators, if applicable, for the duration of the trial and short-acting bronchodilators for 8 hours prior to dosing at each Treatment Visit
- Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)
- Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines
- Female participants of childbearing potential must not be pregnant, breast feeding or lactating and heterosexual female participants of childbearing potential must agree to use, with their partner, a male condom plus an approved method of highly effective birth control from the time of informed consent and for 30 days following the last administered dose
- Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening Visit 1 and a negative urine pregnancy test prior to dosing at each Treatment Visit
- Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent and for 30 days following the last administered dose
Ki nem vehet részt
- Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or hematological conditions within the last 6 months prior to Screening Visit 1
- Current or recent history of medical conditions that are contraindicated for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months prior to Screening Visit 1
- Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
- Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
- Major surgery (requiring general anaesthesia) within 6 weeks prior to Screening Visit 1, or planned surgery through the EOS Visit
- Participation in another investigational drug trial within 30 days of the last dose, 5 half-lives or twice the duration of the biological effect, whichever is longer, prior to Screening Visit 1
- Lower respiratory tract infection within 6 weeks prior to Screening Visit 1
- Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of COPD requiring antibiotic or systemic corticosteroid treatment within 6 months prior to Screening Visit 1
- Prior lung volume reduction surgery or history of chest/lung irradiation
- Daily oxygen therapy for > 12 hours per day
- History of malignancy of any organ system, except for localized skin cancers, within 5 years prior to Screening Visit 1
- History of intolerance or hypersensitivity to any of the ingredients in the formulation for AERO-001, AERO-002, AERO-007, or other aerosol medications
- Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non specific pulmonary diseases
- Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) type 1 and/or 2 antibodies at Screening Visit 1
- Donation of 450 mL of blood within 8 weeks of Screening Visit 1
- History or high risk of noncompliance with trial visits and procedures or unsuitable for entry into the trial at the discretion of the Investigator
- Body mass index >35 kg/m2
- Abnormal and clinically significant 12-lead ECG findings at Screening Visit 1
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
- Chronic obstructive pulmonary disease
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To evaluate the bronchodilator response of LABA (AERO-001, indacaterol) and LAMA (AERO-002, glycopyrrolate) components of AERO-007 following 14 days of treatment in participants with moderate to severe COPD
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment with Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Administered via Nebulization in Participants with Chronic Obstructive Pulmonary Disease (COPD) (AERODUO-2 Trial)
- Kérdések a feltételekről
- Forrás: 2026-527150-39-00: ki vehet részt
- A regiszteradat frissítve
- 2026. november 18.